Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-06-07
2001-09-04
Higel, Floyd D. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C558S445000, C558S346000
Reexamination Certificate
active
06284901
ABSTRACT:
BACKGROUND OF THE INVENTION
Omapatrilat (I) is a potent inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo:
Omapatrilat was developed at the Bristol-Myers Squibb Pharmaceutical Research Institute as the first of a new class of compounds capable of simultaneously inhibiting ACE and NEP and is currently undergoing large scale clinical trials as an anti-hypertensive. See Omapatrilat.
Drugs R D
1999 Apr;1(4):350-1.
Currently, omapatrilat is synthesized using (S)-hydroxy amino acid (II) as one of the key starting materials:
The hydroxyl group of compound (II) must be converted to an aldehyde as a prerequisite step in the synthesis os compound (I), omapatrilat. This oxidation to an aldehyde currently requires several steps and/or noxious reagents. See Robl, J. A., et al.
J. Med. Chem.
1997, 40, 1570-1577; Robl, J. A., et al.
J. Med. Chem.
1996, 39, 494-502.
It is therefore desirable to find alternatives to compound (II) that reduce the number of requisite synthetic steps and eliminate the use of noxious reagents. It is further desirable to develop a pathway suitable for the production of such intermediates.
SUMMARY OF THE INVENTION
The invention is directed to dinitrile intermediates of the formula:
wherein each R
2
is independently selected from:
wherein R
3
, R
4
, R
5
, and R
6
are independently selected from a group consisting of H or C
1
-C
5
alkyl groups and R
7
and R
8
are independently selected from a group consisting of C
1
-C
5
alkyl groups.
The compounds of the invention may be produced by the following schematic pathway:
wherein R
2
is as defined above. This reaction is a step in the production of a racemic mixture of the formula:
The racemic mixture of (V) may then be subjected to a separation process whereby the S-stereoisomer may be isolated. The overall reaction scheme may be summarized as follows:
wherein R
1
is —H, a C
1
-C
5
alkyl group or a benzyl group and each R
2
is as defined above.
As set forth in this reaction pathway, compound (IV) may be an intermediate in the synthesis of hydantoin (III). Hydantoin (III) is used as an intermediate in the synthesis of racemic mixture (V).
The S-stereoisomer of racemic mixture (V) may be used in place of compound (II) in the synthesis of omapatrilat (I).
The use of the S-stereoisomer of racemic mixture (V) with its protected aldehyde avoids the need to oxidize the alcohol on compound (II) and thus reduces the number of steps necessary for the synthesis of omapatrilat and farther avoids the use of noxious chemicals. See Robl, J. A., et al.
J. Med. Chem.
1997, 40, 1570-1577; Robl, J. A., et al.
J. Med. Chem.
1996, 39, 494-502.
Referring to the overall reaction scheme above, hydantoin (III) may be synthesized by one of the two reactions:
Compound (IV) may be synthesized by the following reaction:
Racemic mixture (V) may be synthesized by the following reaction:
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention is directed to the intermediate (IV) containing two nitrile groups:
wherein each R
2
is independently selected from:
and further wherein R
3
, R
4
, R
5
, and R6 are independently selected from the group consisting of —H or a C
1
-C
5
alkyl group. (In a preferred embodiment R
3
, R
4
, R
5
, and R
6
are independently selected from a group consisting of —H or a C
1
-C
3
alkyl group. In a more preferred embodiment R
3
, R
4
, R
5
, and R6 are independently selected from the group consisting of a C
1
-C
3
alkyl group; or R
3
, R
4
, R
5
, and R6 are all —H); and
R
7
and R
8
are independently selected from the group consisting of a C
1
-C
5
alkyl group. In a preferred embodiment R
7
and R
8
are independently selected from a group consisting of a C
1
-C
3
alkyl group.
The inventive process relating to the production of the dinitrile of formula (IV) from the monoacetal of formula (XI) will be referred to herein as “Method C.” “Method C” is part of the overall reaction scheme:
The production of the hydantoin of formula (III) from the dinitrile will be referred to herein as “Method B.” The hydantoin can alternatively be produced directly from the monoacetal of formula (XI). This reaction will be referred to as “Method A.” The production of the racemic mixture of formula (V) from the hydantoin will be referred to as “Method D.”
The dinitrile compound of the invention is used to produce the hydantoin of the formula:
wherein R
1
is —H, a C
1
-C
5
alkyl group or a benzyl group and R
2
is as described above. In a preferred embodiment, R
1
is —H or a C
1
-C
3
alkyl group.
Compound (III) is used as an intermediate in the synthesis of racemic mixture (V):
wherein R
2
is as defined above.
The S stereoisomer of compound (V) may be obtained by subjecting the racemic mixture of formula (V) to amidation in water. A molar excess (generally 10 to 20 percent excess) of acetic anhydride is typically used to ensure complete acylation of all of the nitrogen groups on the compound of formula (V). The reaction is conducted at approximately 35° C. The amide linkage on the desired S-isomer may then be cleaved by enzymatic activity, thereby leaving the undesired R isomer in solution. The free amino acid is then collected and purified. The S-stereoisomer of compound (V) may be purified in the same manner as the (S)-hydroxy amino acid compound (II) with a theoretical yield of 50%. (See Robl, J. A., et al.
J. Med. Chem.
1997, 40, 1570-1577). The purified isomer may then be used to substitute for compound (II) as a synthetic starting material for generating omapatrilat.
An advantage in using compound (V) with its protected aldehyde is that it avoids the need to oxidize the alcohol on compound (II) and thus reduces the number of steps necessary for the synthesis of omapatrilat. It further avoids the use of noxious chemicals often employed in the oxidation of compound (II). See Robl, J. A., et al.
J. Med. Chem.
1997, 40, 1570-1577; Robl, J. A., et al.
J. Med. Chem.
1996, 39, 494-502.
An additional advantage in using compound (III) in the synthesis is the high efficiency evidenced when converting compound (III) to the S stereoisomer of compound (V). Hydantoins, such as compound (III), can be enzymatically racemized so that resolved R stereoisomer can be converted to and purified as the S stereoisomer, thereby increasing the possible yields of the desired S stereoisomer.
Compound (III) may be synthesized by either Method A or Method B. Method A is summarized below:
Any alkali cyanide, such as LiCN, as well as any organic cyanohydrin, such as a C
1
-C
6
aliphatic cyanohydrin, may be used in place of NaCN in Method A. The reaction scheme for Method A presented above illustrates the use of a H
2
O/EtOH blend as reaction medium, though a pure aqueous reaction medium may be used. The alcohol, which may be either methanol, ethanol, isopropyl alcohol, propyl alcohol, butyl alcohol or i-butyl alcohol, increases the solubility of the monoacetal of formula (I) in water. Typically, the weight ratio of water:C
1
-C
4
alcohol in the reaction medium is 1:1 or more. The weight ratio of monoacetal:cyanide compound is typically between 2:1. The weight ratio of cyanide:ammonium carbonate is generally 1:13; and the weight ratio of reaction medium:monoacetal is typically 28: 1.
In a preferred embodiment, the reaction mixture is heated above room temperature, (20° C.). In a more preferred embodiment, the reaction mixture is heated to about 50° C. to about 57° C. The reaction mixture is allowed to react for a time sufficient to effectuate the reaction, preferably more than 2 hrs and more preferably greater than 6 hrs and even more preferably greater than 12 hours. In a preferred embodiment, the reaction product is recovered by adjusting the system pH from about 6 to about 10, preferably about 7, at which time the reaction product forms a solid white powder. The reaction is conducted at ambient pressure. Method (A) may further generate a minor amount of compound (IV) as an intermediate chemical species.
The dinitrile compound of the invention, formula
Brown Robert G.
Raff Dwight E.
Rongione Joseph C.
Dixie Chemical Company
Higel Floyd D.
Locke Liddell & Sapp LLP
Saeed Kamal
LandOfFree
Dinitrile intermediates for the synthesis of omapatrilat and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dinitrile intermediates for the synthesis of omapatrilat and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dinitrile intermediates for the synthesis of omapatrilat and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2467198